Harnessing PROTAC technology to combat stress hormone receptor activation

Nat Commun. 2023 Dec 9;14(1):8177. doi: 10.1038/s41467-023-44031-2.

Abstract

Counteracting the overactivation of glucocorticoid receptors (GR) is an important therapeutic goal in stress-related psychiatry and beyond. The only clinically approved GR antagonist lacks selectivity and induces unwanted side effects. To complement existing tools of small-molecule-based inhibitors, we present a highly potent, catalytically-driven GR degrader, KH-103, based on proteolysis-targeting chimera technology. This selective degrader enables immediate and reversible GR depletion that is independent of genetic manipulation and circumvents transcriptional adaptations to inhibition. KH-103 achieves passive inhibition, preventing agonistic induction of gene expression, and significantly averts the GR's genomic effects compared to two currently available inhibitors. Application in primary-neuron cultures revealed the dependency of a glucocorticoid-induced increase in spontaneous calcium activity on GR. Finally, we present a proof of concept for application in vivo. KH-103 opens opportunities for a more lucid interpretation of GR functions with translational potential.

MeSH terms

  • Glucocorticoids* / pharmacology
  • Receptors, Glucocorticoid* / metabolism

Substances

  • Glucocorticoids
  • Receptors, Glucocorticoid